Thalidomide

Thalidomide
IUPAC name	(RS)-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione
Tradename	Contergan, Thalomid, others
CAS number	50-35-1
DrugBank	DB01041
UNII	4Z8R6ORS6L

Thalidomide. First marketed in the late 1950s by the West German company Chemie Grünenthal as a sedative, it became infamous for causing severe birth defects when taken by pregnant women. Initially perceived as safe, it was withdrawn globally by the early 1960s, but later re-emerged as a critical treatment for conditions like leprosy and multiple myeloma. Its complex history spans a major pharmaceutical scandal, significant changes in drug regulation, and ongoing biomedical research.

History

Developed in West Germany by the pharmaceutical firm Chemie Grünenthal, it was first sold in 1957 under the brand name Contergan. It was aggressively marketed across Europe, Australia, and Canada as a safe hypnotic and anti-emetic for morning sickness, without adequate teratogenic testing. The drug was never approved by the Food and Drug Administration in the United States, largely due to the efforts of reviewer Frances Oldham Kelsey. By 1961, a dramatic increase in phocomelia and other congenital malformations was linked to its use by obstetrician Widukind Lenz and independently by Australian doctor William McBride. This led to its withdrawal from most markets, triggering a worldwide scandal and major reforms, including the Kefauver-Harris Amendment which strengthened the Food, Drug, and Cosmetic Act.

Medical uses

Under strict risk management programs like System for Thalidomide Education and Prescribing Safety, it is approved for specific conditions. It is a primary treatment for erythema nodosum leprosum, a painful complication of Hansen's disease. In oncology, it is a standard therapy for multiple myeloma, often in combination with dexamethasone. It is also used for the treatment of myelodysplastic syndrome and certain manifestations of HIV/AIDS, such as aphthous ulcers. Its use is absolutely contraindicated during pregnancy due to its potent teratogenicity.

Mechanism of action

Its biological activity is complex and multifaceted, involving several biochemical pathways. A primary mechanism is the inhibition of angiogenesis, the formation of new blood vessels, which is crucial for tumor growth and fetal development. It acts as an immunomodulatory drug by altering levels of cytokines such as tumor necrosis factor-alpha. Furthermore, it promotes the ubiquitin-mediated degradation of specific proteins, including transcription factors like Ikaros family and Aiolos, which are vital for B cell and T cell function. These actions on the immune system and cellular proliferation underpin its efficacy in both cancer and inflammatory disease.

Adverse effects

The most catastrophic effect is severe birth defects, including phocomelia, amelia, and malformations of the heart, kidney, and ears, when exposed in utero. Common side effects in adults include peripheral neuropathy, sedation, constipation, and skin rash. It also increases the risk of venous thromboembolism, particularly when used with chemotherapy agents like doxorubicin. Other significant risks include bradycardia and the potential for severe dermatological reactions such as Stevens-Johnson syndrome. These risks mandate rigorous patient monitoring and contraception protocols.

Society and culture

The disaster had a profound impact on pharmaceutical law and public trust, leading to the establishment of robust regulatory agencies like the Medicines and Healthcare products Regulatory Agency in the United Kingdom. Survivors, known as "Thalidomiders," formed advocacy groups such as The Thalidomide Society and have been involved in long-term legal battles for compensation against companies like Distillers Company and Chemie Grünenthal. The event has been depicted in numerous media works, including the BBC drama *Attachments*, and remains a central case study in bioethics and medical jurisprudence.

Research

Ongoing investigations focus on developing safer analogues known as immunomodulatory imide drugs, which include lenalidomide and pomalidomide. These derivatives retain therapeutic benefits while aiming to reduce teratogenic and neuropathic effects. Current clinical trials are exploring its potential in treating other conditions, such as Crohn's disease, Kaposi's sarcoma, and various solid tumors. Research also continues into its precise molecular targets within the cereblon complex and its role in protein homeostasis. Studies of the Thalidomide Victims Association of Canada cohort continue to provide long-term data on the health of survivors.

Category:Drugs Category:Teratogens Category:Immunomodulating drugs